Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Vicadrostat
- DRUG Placebo matching Vicadrostat
Study Locations (20)
California
- National Heart Institute - Beverly Hills — Beverly Hills
- Hope Clinical Research — Canoga Park
- John Muir Physician Network Clinical Research Center — Concord
- Velocity Clinical Research-Huntington Park — Huntington Park
- Velocity Clinical Research, San Diego — La Mesa
- First Valley Medical Group — Lancaster
- ARK Clinical Research — Long Beach
- Diabetes Associates Medical Group — Orange
- Empire Clinical Research — Pomona
- Velocity Clinical Research - San Bernardino — San Bernardino
- Acclaim Clinical Research — San Diego
Arizona
- Arizona Clinical Trials - Chandler — Chandler
- Elite Clinical Studies — Phoenix
- Clinical Research Institute of Arizona, LLC — Sun City West
- Fiel Family & Sports Medicine — Tempe
- Arizona Clinical Trials — Tucson
- Yuma Clinical Trials — Yuma
Alabama
- Pinnacle Research Group, LLC — Anniston
- Eastern Shore Research Group — Fairhope
- Lakeview Clinical Research — Guntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,800 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2029-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07064473
The ClinicalTrials.gov registry entry for NCT07064473 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 11,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions — of which Empagliflozin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07064473 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07064473 about?
NCT07064473 is a clinical study titled "EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease". This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empaglifl...
What is the current status of trial NCT07064473?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 11,800 participants. The study started on 2025-05-09. Estimated completion is 2029-12-21.
What conditions does trial NCT07064473 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus, Type 2, Cardiovascular Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07064473?
The interventions under investigation include: Empagliflozin (DRUG), Vicadrostat (DRUG), Placebo matching Vicadrostat (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07064473?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07064473 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.